In Brief: Bristol-Myers Squibb
Executive Summary
Bristol-Myers Squibb: Maxipime (cefepime) will be reviewed for treatment of febrile episodes in neutropenic patients March 5 by the Anti-Infective Drugs Advisory Committee at a meeting held at the Ramada Inn in Bethesda, Md. The open public hearing begins at 8:30. In the afternoon of March 5 and all of March 6 and 7, committee will discuss document to industry on evaluability criteria for review of anti-microbials at the Division of Anti-Infective Drug Products. Copies of the draft document can be obtained two weeks before the meeting by calling (301) 827-4573. On March 6 and 7, the meeting will be held at the Bethesda Holiday Inn...